Advice
following an abbreviated submission
tafluprost 15 micrograms/mL and timolol 5mg/mL preservative-free eye drops (Taptiqom®) are accepted for restricted use within NHS Scotland.
Indication under review: Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops.
SMC restriction: to use in patients who have proven sensitivity to preservatives.
The combination product costs less than preservative-free tafluprost and timolol eye drops administered separately.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- tafluprost + timolol (Taptiqom)
- SMC ID:
- 1085/15
- Indication:
- Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops
- Pharmaceutical company
- Santen
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 07 September 2015